We Spent $724,637 Testing Rapamycin. What We Found Shocked Us.

Brad Stanfield designed this protocol after reviewing preclinical data showing aged muscle has mTOR hyperactivation and impaired autophagy. The exercise was deliberately moderate and home‑based to ensure safety and adherence. The 30‑second chair stand test was the primary outcome. The trial was pre‑registered, and all analyses were pre‑specified. The completers and per‑protocol analyses both suggested a dose–response blunting of gains. Adverse events were mostly exercise‑related muscle aches, but one patient developed pneumonia a few days after the first dose, raising the well‑known immunosuppression risk. The authors now believe this cycling interval is too short and advocate for longer inter‑dose periods (3–6 weeks) and a washout period in future trials.

Kaeberlein suggests that in the current trial, the rapamycin group might have eventually caught up if allowed a 12‑week washout. He speculates that after clearing the drug, the muscle’s anabolic response could be enhanced because of prior autophagy‑driven housekeeping. This idea is based on preclinical observations where cessation of mTOR inhibition after a sustained period leads to a robust functional rebound, possibly due to stem‑cell rejuvenation. However, he acknowledges this is entirely speculative and would require a large, expensive trial to test.

Brad Stanfield and Matt Kaeberlein designed the trial to recruit sedentary older adults (65–85) to maximise the signal from a 12‑week exercise programme. They used 6 mg of sirolimus (Pfizer’s Rapamune, not a generic) to ensure consistent dosing and a whole‑capsule approach to maintain enteric coating. The primary endpoint was the 30‑second chair stand test, a sensitive marker of muscle power. The pre‑registered analysis included intention‑to‑treat, completers, and per‑protocol populations. The primary ITT analysis did not reach significance (placebo improved more, but not statistically). In the per‑protocol analysis (≥75% adherence), the effect size widened in favour of placebo, suggesting a dose‑response relationship with adherence. All secondary muscle endpoints trended in the same direction. The speakers believe this is a real signal, though sensitivity analyses carry a higher risk of false positives. They note this is the first human study where rapamycin clearly underperformed placebo on a muscle‑performance endpoint, contrasting with the PEARL trial’s positive body‑composition changes in women over 48 weeks. This forces a re‑examination of dosing frequency, drug exposure during exercise, and the possibility that a washout period might reverse the effect.

The study protocol had participants exercise Monday, Wednesday, Friday and take rapamycin on Saturday, hoping that by Monday most of the drug would be cleared. However, pharmacokinetic data from a University of Arizona trial (50 people, 4 mg and 8 mg once‑weekly) shows that most people still have detectable, albeit low, rapamycin levels at day 2 and day 3. Thus, the first exercise session of the week likely occurred under some degree of mTORC1 inhibition. Kaeberlein notes that serum levels are not tissue levels; rapamycin could accumulate in muscle and other organs even when blood levels are undetectable. This led the authors to propose that future studies should explore intervals of 3 to 6 weeks between doses to ensure a true washout.

Kaeberlein elaborates that inflammation‑driven endpoints (e.g., brain, immune) might require a block of continuous mTOR inhibition to reset the inflammatory milieu, after which a washout period may reveal functional improvements. For muscle, where adaptation to exercise requires acute mTOR activation, even low residual rapamycin could blunt gains. He notes that we lack good human data to choose between 1‑week, 2‑week, or longer intervals, and that different tissues may have different therapeutic windows. This is a call for more nuanced trial designs rather than assuming a single weekly pill is optimal for all aging phenotypes.